Notable Labs Corp (NTBL) - Rentabilitas operasi

Logo perusahaan publik Notable Labs Corp (NTBL)

The investment potential of Notable Labs, Ltd. (NTBL) is based on outsourcing the development of AI algorithms to external partners to concentrate on personalized therapy. Operating profit margins illustrate this approach, where the 0.00 level captures recent values. Efficiency is confirmed by scalable, high-margin tumor analysis software and the retention of rare specialists through a stock option system.

NTBL: Rentabilitas dodolan operasi Notable Labs Ltd 21.02.2024 - 02.11.2024

Rincian metrik komprehensif lan analitis Notable Labs, Ltd. (NTBL)

- rega saham lan konsensus proyeksi valuasi:
Analisis dhasar perusahaan:Notable Labs Inc., NTBL
Barang utama Notable Labs Corp

For precision oncology innovator Notable Labs, Ltd. (NTBL), the commercialization efficiency of its prediction platform is directly reflected in the operating margin. This operating profitability measures the share of profit from core business operations before financial expenses and taxes, allowing investors to assess the company's actual ability to generate cash flow from its unique therapy selection process, excluding external marketing noise.

Pesaing wigati

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|WHWK (Aadi Bioscience, Inc.) - Margin operasi|TCRX (TScan Therapeutics) - Rasio bathi operasi|Rentabilitas operasi Champions Oncology (CSBR)|Rentabilitas kegiatan operasi XBiotech USA|Rentabilitas operasi CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Rentabilitas dodolan operasi|RADX - Rentabilitas operasi|ARTV - Margin operasi|Adlai Nortye Ltd (ANL) - Rentabilitas operasi|Veru Pharma - Tingkat bathi operasi|Rentabilitas operasi Tempest Therapeutics Corp|Rentabilitas dodolan miturut bathi operasi XLO (Xilio Therapeutics, Inc.)|Margin operasi RENB|MURA (Mural Oncology) - Tingkat bathi operasi|Margin operasi KAPA (Kairos Pharma Ltd)|OKUR: Rentabilitas dodolan miturut bathi operasi|GDTC: Margin dodolan operasi|CRIS - Margin operasi|APLM: Margin operasi|Rentabilitas dodolan operasi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Margin operasi|Margin operasi Genprex Inc.|Margin operasi CLDI|Margin dodolan operasi Sunshine Biopharma, Inc. SBFM|Margin operasi XBIO (Xenetic Biosciences)|Tingkat bathi operasi SLRX|PPBT - Rentabilitas operasi|AONC (aoncology.com) - Rentabilitas dodolan miturut bathi operasi|BGNE: Margin operasi|Checkpoint Therapeutics Inc (CKPT) - Margin operasi|ELEV (Elevation Oncology Inc.) - Margin operasi|icadmed.com (ICAD) - Rentabilitas kegiatan operasi|Margin operasi IKNA|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi